ALK and neoplasm: The ATLANTIC study demonstrated that an objective response was achieved in 12.2% patients who had EGFR+/ALK+ NSCLC with tumor cell PD‐L1 expression ≥25%, treated with durvalumab (anti‐PD‐L1).22